Loading clinical trials...
Loading clinical trials...
A Phase 3, 2-Part, Open-Label Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Ivacaftor in Subjects With Cystic Fibrosis Who Are 2 Through 5 Years of Age and Have a CFTR Gating Mutation
Conditions
Interventions
Ivacaftor
Locations
20
United States
Birmingham, Alabama, United States
Aurora, Colorado, United States
Atlanta, Georgia, United States
Indianapolis, Indiana, United States
Lexington, Kentucky, United States
Boston, Massachusetts, United States
Start Date
January 1, 2013
Primary Completion Date
March 1, 2014
Completion Date
March 1, 2014
Last Updated
April 5, 2016
NCT02417740
NCT06616857
NCT02740868
NCT07108153
NCT07274631
NCT07303621
Lead Sponsor
Vertex Pharmaceuticals Incorporated
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions